Bing Qiao1, Jie Deng2, Yi Li2, Xiaozeng Wang2, Yaling Han2. 1. Department of Outpatient of 61905 PLA (The Chinese People's Liberation Army) Troops, The General Hospital of Shenyang Military Region, Chinese People's Liberation Army No. 83 Wenhua Road, Shenyang 100840, China. 2. Department of Cardiology, The General Hospital of Shenyang Military Region, Chinese People's Liberation Army No. 83 Wenhua Road, Shenyang 100840, China.
Abstract
BACKGROUND: The protective effect of statins against CIN is still controversial. We investigated the efficacy of pretreatment of rosuvastatin in decreasing the risk of CIN in a high-risk population of patients undergoing coronary angiography. METHODS: We conducted a prospective, randomized, controlled study, involving 120 patients with diabetes and mild to moderate renal dysfunction undergoing coronary angioplasty. Patients were randomly assigned to receive rosuvastatin (n = 60, 10 mg/day) or no statins (n = 60) for at least 2 days before and 3 days after contrast media administration. Serum cystatin (SCysC), serum neutrophil gelatinase-associated lipocalin (NGAL) and urinary N-acetyl-β-D-glucosaminidase/urinary creatinine (NAG/UCr) were also observed before and after procedure. RESULTS:Baseline demographic characteristics and nephropathy risk factors were similar between groups. The NGAL levels after procedure were higher than baseline (P < 0.05). Both the peak NGAL values occurred at 2 hours. In rosuvastatin group the peak NGAL values were lower compared with that in control group [(47.60 ± 18.72) μg/L vs (62.19 ± 44.68) μg/L, P = 0.014]. No differences of the peak values of SCr were found between the two groups. But the peak levels of SCysC in rosuvastatin group were significantly lower compared with that in control group [(0.96 ± 0.30) mg/L vs (1.08 ± 0.34) mg/L, P = 0.043]. There were significant statistical differences of NAG/Cr levels in the two groups. No clinical events occurred within the following 30 days in the two groups. CONCLUSIONS:Rosuvastatin could reduce the effect of degrading glomerular filtration function and renal tubular damage in patients with DM and mild to moderate renal dysfunction.
RCT Entities:
BACKGROUND: The protective effect of statins against CIN is still controversial. We investigated the efficacy of pretreatment of rosuvastatin in decreasing the risk of CIN in a high-risk population of patients undergoing coronary angiography. METHODS: We conducted a prospective, randomized, controlled study, involving 120 patients with diabetes and mild to moderate renal dysfunction undergoing coronary angioplasty. Patients were randomly assigned to receive rosuvastatin (n = 60, 10 mg/day) or no statins (n = 60) for at least 2 days before and 3 days after contrast media administration. Serum cystatin (SCysC), serum neutrophil gelatinase-associated lipocalin (NGAL) and urinary N-acetyl-β-D-glucosaminidase/urinary creatinine (NAG/UCr) were also observed before and after procedure. RESULTS: Baseline demographic characteristics and nephropathy risk factors were similar between groups. The NGAL levels after procedure were higher than baseline (P < 0.05). Both the peak NGAL values occurred at 2 hours. In rosuvastatin group the peak NGAL values were lower compared with that in control group [(47.60 ± 18.72) μg/L vs (62.19 ± 44.68) μg/L, P = 0.014]. No differences of the peak values of SCr were found between the two groups. But the peak levels of SCysC in rosuvastatin group were significantly lower compared with that in control group [(0.96 ± 0.30) mg/L vs (1.08 ± 0.34) mg/L, P = 0.043]. There were significant statistical differences of NAG/Cr levels in the two groups. No clinical events occurred within the following 30 days in the two groups. CONCLUSIONS:Rosuvastatin could reduce the effect of degrading glomerular filtration function and renal tubular damage in patients with DM and mild to moderate renal dysfunction.
Authors: Peter A McCullough; Andy Adam; Christoph R Becker; Charles Davidson; Norbert Lameire; Fulvio Stacul; James Tumlin Journal: Am J Cardiol Date: 2006-02-23 Impact factor: 2.778
Authors: Vishal S Vaidya; Sushrut S Waikar; Michael A Ferguson; Fitz B Collings; Kelsey Sunderland; Costas Gioules; Gary Bradwin; Roland Matsouaka; Rebecca A Betensky; Gary C Curhan; Joseph V Bonventre Journal: Clin Transl Sci Date: 2008-12 Impact factor: 4.689
Authors: Sanjaya Khanal; Nizar Attallah; Dean E Smith; Eva Kline-Rogers; David Share; Michael J O'Donnell; Mauro Moscucci Journal: Am J Med Date: 2005-08 Impact factor: 4.965
Authors: Giuseppe Patti; Annunziata Nusca; Massimo Chello; Vincenzo Pasceri; Andrea D'Ambrosio; George W Vetrovec; Germano Di Sciascio Journal: Am J Cardiol Date: 2007-12-21 Impact factor: 2.778
Authors: O Hernández-Perera; D Pérez-Sala; J Navarro-Antolín; R Sánchez-Pascuala; G Hernández; C Díaz; S Lamas Journal: J Clin Invest Date: 1998-06-15 Impact factor: 14.808